• search
For Quick Alerts
ALLOW NOTIFICATIONS  
For Daily Alerts

Killer T-cells: Oxford University COVID-19 vaccine hopes rise with strong trial results

|

London, July 16: Researchers at the University of Oxford believe they may have a breakthrough in their search for a COVID-19 vaccine after the team discovered that the jab could provide "double protection" against the deadly coronavirus following early-stage human trials, according to media reports in the UK.

Oxford University COVID-19 vaccine hopes rise with strong trial results

Blood samples taken from a group of UK volunteers given a dose of the vaccine showed that it stimulated the body to produce both antibodies and "killer T-cells", a senior source from the trial was quoted by 'The Daily Telegraph' as saying.

8 world leaders join hands to seek equal access to COVID-19 vaccine

The discovery is promising because separate studies have suggested that antibodies may fade away within months while T-cells can stay in circulation for years. However, the source cautioned that the results, while "extremely promising", did not yet prove that the Oxford vaccine provides long-lasting immunity against the deadly virus.

"I can tell you that we now know the Oxford vaccine covers both bases - it produces both a T cell and an antibody response. It's the combination of these two that will hopefully keep people safe. So far, so good. It's an important moment. But we still have a long way to go," the source said.

Another source close to the team described the presence of both antibodies and T-cells as a "double defence" against COVID-19. 'The Lancet' medical journal has confirmed that it would be publishing early-stage human trial data from the Oxford team on Monday. David Carpenter, chairman of the Berkshire Research Ethics Committee, which approved the Oxford trial, said the vaccine team was "absolutely on track".

Human trials of second COVID-19 vaccine candidate begin

"Nobody can put final dates... things might go wrong but the reality is that by working with a big pharma company, that vaccine could be fairly widely available around September and that is the sort of target they are working on," he said.

    International flights: Bubble travel with US & France, flights to resume from tomorrow|Oneindia News

    The vaccine development, by the university's Jenner Institute, is being supported by the UK government and AstraZeneca, which will support the production phase. The pharmaceutical company said last month that phase one trials were due to finish and a phase three trial had begun which will see the vaccine given to thousands of people so it can be tested for efficacy and safety.

    "The COVID-19 vaccine trial team have been working hard on assessing the safety and immunogenicity of ChAdOx1 nCoV-19, and preparing to assess vaccine efficacy," Sarah Gilbert, professor of vaccinology at the university's Jenner Institute who is leading the research, had said back in May.

    The vaccine, named ChAdOx1 nCoV-19, is based on a weakened version of the common cold that causes infections in chimpanzees. It also contains the genetic material of the spike protein of SARS-CoV-2 - the strain of coronavirus that causes the COVID-19 illness.

    The Oxford University vaccine is one of more than 100 in development as the novel coronavirus continues to spread - infecting more than 13 million people and killing at least 582,000 worldwide.

    For Daily Alerts
    Get Instant News Updates
    Enable
    x
    Notification Settings X
    Time Settings
    Done
    Clear Notification X
    Do you want to clear all the notifications from your inbox?
    Settings X
    X
    We use cookies to ensure that we give you the best experience on our website. This includes cookies from third party social media websites and ad networks. Such third party cookies may track your use on Oneindia sites for better rendering. Our partners use cookies to ensure we show you advertising that is relevant to you. If you continue without changing your settings, we'll assume that you are happy to receive all cookies on Oneindia website. However, you can change your cookie settings at any time. Learn more